None of the current guidelines recommend antiviral therapy for inactive hepatitis B virus (HBV) carriers (IHCs).
Methods
In this real-world, multicenter, nonrandomized study, 32 participants meeting the inclusion criteria were enrolled 1:1 for treatment with peginterferon α-2b or monitoring without treatment based on participant preference. The expected treatment duration was 48 weeks. The primary end point was hepatitis B surface antigen (HBsAg) loss. The HBV vaccine could be injected after HBsAg loss.
Results
All patients had HBsAg levels of <20 IU/mL. The mean baseline HBsAg levels were 6.6 IU/mL and 5.8 IU/mL in the treated and untreated groups, respectively. Fifteen (93.8%) participants achieved HBsAg loss, 5 obtained HBsAg seroconversion after undergoing a mean of 19.7 weeks of therapy in the treated group, and no one in the follow-up group achieved HBsAg loss during a mean follow-up time of 12.6 months (P < .0001). Generally, the therapy was well tolerated. Nine of 11 individuals who exhibited HBsAg loss benefited from receiving the HBV vaccine.
Conclusions
This study provides justification for further studies of short-course peginterferon α-2b for the functional cure of IHCs with low HBsAg levels. Additionally, HBV vaccine injection is beneficial after interferon-induced HBsAg loss.
functional cure, hepatitis B surface antigen loss, hepatitis B vaccine, inactive hepatitis B virus carrier, peginterferon α-2b
Topic:
surface antigens follow-up hepatitis b surface antigens hepatitis b, chronic hepatitis b virus viruses hepatitis b vaccines peginterferon
Issue Section:
Major Article 作者: StephenW 时间: 2020-7-5 15:13
所有患者的HBsAg水平均<20 IU / mL。治疗组和未治疗组的平均基线HBsAg水平分别为6.6 IU / mL和5.8 IU / mL。治疗组平均接受19.7周的治疗后有15名(93.8%)参与者达到了HBsAg丢失,治疗组中有5位获得了HBsAg血清转化,随访组中没有人在平均12.6个月的平均随访时间内达到HBsAg丢失(P <.0001)。通常,该疗法耐受良好。表现出HBsAg缺失的11个人中有9个人从接受HBV疫苗中受益。
结论